2-(4-联苯基)-2-(boc-氨基)乙酸 | 369403-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-联苯基)-2-(boc-氨基)乙酸
• 中文别名: 2-(4-联苯基)-2-(BOC-氨基)乙酸
• 英文名称: 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid
• 英文别名: 2-[(tert-butoxy)carbonylamino]-2-(4-phenylphenyl)acetic acid；2-(4-Biphenylyl)-2-(Boc-amino)acetic Acid；2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(4-phenylphenyl)acetic acid
• CAS: 369403-44-1
• 化学式: C₁₉H₂₁NO₄
• 分子量: 327.38
• InChiKey: IGQRMCQSKDTFDV-UHFFFAOYSA-N

物化性质

• 沸点：
  512.4±50.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-(4-联苯基)-2-(boc-氨基)乙酸 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以2.11 g的产率得到2-氨基-2-(4-联苯)乙酸
  参考文献：
  名称：

  2-([1,1’-联苯]-4-基)-2-甘氨酸类化合物的合成方法

  摘要：

  本发明涉及一种2‑([1,1'‑联苯]‑4‑基)‑2‑甘氨酸类化合物的合成方法，包括在惰性气体保护和微波辅助条件下，使式I所示化合物和式II所示化合物在碱、溶剂和催化剂存在下进行suzuki反应，制得中间体化合物，然后使中间体化合物脱保护，制得式III所示化合物；其中，式I所示化合物的结构式为：式II所示化合物的结构式为：式III所示化合物的结构式为：式I和式III中，R为H、烷基、烷氧基、卤素、三氟甲基中的一种。本发明合成方法毒性较低，安全系数较高，操作简便易控制，且反应高效，产率高达81％以上。本发明合成方法中，在suzuki反应过程中增加一定时间的微波辅助，有助于促进反应进行，有效提高反应效率，缩短反应时间。

  公开号：

  CN111848430B
• 作为产物：
  描述：

  Dl-4-溴苯甘氨酸 在 bis-triphenylphosphine-palladium(II) chloride 、 盐酸羟胺 、 sodium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.0h， 生成 2-(4-联苯基)-2-(boc-氨基)乙酸 、 tert-butyl (1-([1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

  摘要：

  Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PIA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.01.015

文献信息

• Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
  申请人：Tachdjian Catherine

  公开号：US20070003680A1

  公开（公告）日：2007-01-04

  The inventions disclosed herein relate to man-made bi-aromatic amide compounds that, when contacted with comestible food or drinks or pharmaceutical compositions at concentrations preferably on the order of about 100 ppm or lower, serve as sweet taste modifiers, sweet flavoring agents, or sweet flavor enhancers, for use in foods, beverages, and other comestible products, or orally administered medicinal products or compositions, optionally in the presence of or in mixtures with conventional flavoring agents such as known natural saccharide sweeteners and previously known artificial sweeteners.

  本发明涉及人工合成的双芳香酰胺化合物，当与食品、饮料或制药组合物接触时，其浓度最好在约100 ppm或更低的范围内，可用作甜味改良剂、甜味调味剂或甜味增强剂，用于食品、饮料和其他可食用产品，或口服药物产品或组合物，可选地与已知的天然糖类甜味剂和以前已知的人工甜味剂等传统调味剂混合使用。
• Inhibitors of anthrax lethal factor
  申请人：Rideout Darryl

  公开号：US20070197577A1

  公开（公告）日：2007-08-23

  Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.

  通过抑制炭疽病致命因子（LF）活性，预防和治疗炭疽感染的方法，化合物和组合物。
• [EN] INHIBITORS OF ANTHRAX LETHAL FACTOR<br/>[FR] INHIBITEURS DU FACTEUR LETAL DU CHARBON
  申请人：CENGENT THERAPEUTICS

  公开号：WO2005027856A3

  公开（公告）日：2006-10-12
• US7842324B2
  申请人：——

  公开号：US7842324B2

  公开（公告）日：2010-11-30
• Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions
  作者：Nyssa Drinkwater、Natalie B. Vinh、Shailesh N. Mistry、Rebecca S. Bamert、Chiara Ruggeri、John P. Holleran、Sasdekumar Loganathan、Alessandro Paiardini、Susan A. Charman、Andrew K. Powell、Vicky M. Avery、Sheena McGowan、Peter J. Scammells

  DOI：10.1016/j.ejmech.2016.01.015

  日期：2016.3

  Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PIA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics. (C) 2016 Elsevier Masson SAS. All rights reserved.